Oral Metronidazole
Preclinical
Oral Metronidazole is one of 12 therapeutic programs targeting Bacterial Vaginosis. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
11
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
16 competitors in Bacterial Vaginosis
#DrugCompanyPhaseTrials
1Flagyl
DDePuy Orthopaedics
Approved
Acanya
PfizerApproved
Decadron
AAspen Global Incorporated
Approved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Mycostatin
GGood Molecules, LLC
Approved
Lotrimin
BayerPhase 3
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Rocephin
CConrado Roberto Hoffmann Filho
Phase 3
Doxycyclin
TTanta University
Phase 3
Metronidazole Suppositories
PPeking University Shenzhen Hospital
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Oral Metronidazole. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]
- Company
- DDouglas Kwon